Lonza Group AG: Lonza and Moderna Enter New Agreement to Double Drug Substance Production for COVID-19 Vaccine in Visp
New agreement for three further production lines at Lonza s site in Visp, Switzerland
Additional production lines will come online sequentially
All three are expected to be operational in the earlier part of 2022
Quote from Pierre-Alain Ruffieux, CEO, Lonza: Since we began working with Moderna in May 2020, its mRNA vaccine has proved to be pivotal in controlling the COVID-19 pandemic. We have commenced and ramped up operations in our four existing production lines at an unprecedented rate and scale. Our new agreement with Moderna will double our drug substance manufacturing capacity in Visp (CH), at this time of urgent global demand. We are proud of our work with Moderna, and we are looking forward to expanding the partnership in the coming months.